Subcutaneous daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.

Authors
Publication date
1 January 2021
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:3196681
    Last time updated on 10/02/2023